| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alleviation of radiotherapy-induced oral mucositis
|
Gourd, Elizabeth
|
|
|
20 |
12 |
p. e664
|
artikel
|
| 2 |
Androgen receptor-targeted agents in the management of advanced prostate cancer
|
Tombal, Bertrand
|
|
|
20 |
12 |
p. 1628-1630
|
artikel
|
| 3 |
A promising therapeutic vaccine for cervical precancer
|
Das, Manjulika
|
|
|
20 |
12 |
p. e671
|
artikel
|
| 4 |
Are health-care policies restricting further progress in cancer survival outcomes?
|
Patel, Reena
|
|
|
20 |
12 |
p. e657
|
artikel
|
| 5 |
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
|
Rosell, Rafael
|
|
|
20 |
12 |
p. 1617-1618
|
artikel
|
| 6 |
Artificial intelligence in gastrointestinal endoscopy: how intelligent can it get?
|
Ragunath, Krish
|
|
|
20 |
12 |
p. 1616-1617
|
artikel
|
| 7 |
Cancer and therapy in the 16th century: the unique case of adenocarcinoma in Luigi Carafa, prince of Stigliano (1511–76)
|
Fornaciari, Antonio
|
|
|
20 |
12 |
p. 1641-1642
|
artikel
|
| 8 |
Cancer prevention and treatment in humanitarian settings: an urgent and unmet need
|
Alawa, Jude
|
|
|
20 |
12 |
p. 1635-1636
|
artikel
|
| 9 |
CAR T-cell cocktail therapy for B-cell malignancies
|
Gourd, Elizabeth
|
|
|
20 |
12 |
p. e669
|
artikel
|
| 10 |
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer
|
Zhou, Qi
|
|
|
20 |
12 |
p. e654
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 1342–44
|
|
|
|
20 |
12 |
p. e663
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 383–93
|
|
|
|
20 |
12 |
p. e663
|
artikel
|
| 13 |
Correction to Lancet Oncol 2019; 20: 1544–55
|
|
|
|
20 |
12 |
p. e663
|
artikel
|
| 14 |
Correction to Lancet Oncol 2019; 20: 1349–59
|
|
|
|
20 |
12 |
p. e663
|
artikel
|
| 15 |
Correction to Lancet Oncol 2019; 20: e645–52
|
|
|
|
20 |
12 |
p. e663
|
artikel
|
| 16 |
Denosumab for giant cell tumour of bone: success and limitations
|
Healey, John H
|
|
|
20 |
12 |
p. 1627-1628
|
artikel
|
| 17 |
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
|
Chawla, Sant
|
|
|
20 |
12 |
p. 1719-1729
|
artikel
|
| 18 |
EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma
|
Franceschi, Enrico
|
|
|
20 |
12 |
p. e715-e728
|
artikel
|
| 19 |
Early intervention effective in smouldering multiple myeloma
|
Gourd, Elizabeth
|
|
|
20 |
12 |
p. e666
|
artikel
|
| 20 |
Endocrine-based therapy versus chemotherapy in advanced breast cancer
|
Robert, Marie
|
|
|
20 |
12 |
p. 1632-1633
|
artikel
|
| 21 |
Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16
|
Loucaides, Eva M
|
|
|
20 |
12 |
p. e672-e684
|
artikel
|
| 22 |
2019 international clinical practice guidelines for the treatment of venous thromboembolism
|
Thein, Kyaw Zin
|
|
|
20 |
12 |
p. e655
|
artikel
|
| 23 |
2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply
|
Douketis, James D
|
|
|
20 |
12 |
p. e656
|
artikel
|
| 24 |
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
|
Ahn, Myung-Ju
|
|
|
20 |
12 |
p. 1681-1690
|
artikel
|
| 25 |
LEEP for cervical neoplasia recurrence in HIV-positive patients
|
Das, Manjulika
|
|
|
20 |
12 |
p. e667
|
artikel
|
| 26 |
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
|
Drayson, Mark T
|
|
|
20 |
12 |
p. 1760-1772
|
artikel
|
| 27 |
Lorlatinib: a new treatment option for ROS1-positive lung cancer
|
Duruisseaux, Michaël
|
|
|
20 |
12 |
p. 1622-1623
|
artikel
|
| 28 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
|
Shaw, Alice T
|
|
|
20 |
12 |
p. 1691-1701
|
artikel
|
| 29 |
Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
|
Prasad, Vinay
|
|
|
20 |
12 |
p. 1638-1640
|
artikel
|
| 30 |
New smoking ban for restaurants and bars in Austria
|
Burki, Talha Khan
|
|
|
20 |
12 |
p. e668
|
artikel
|
| 31 |
New treatment option for relapsed or refractory DLBCL
|
Gourd, Elizabeth
|
|
|
20 |
12 |
p. e670
|
artikel
|
| 32 |
Optimal patient selection for stereotactic body radiotherapy
|
Kishan, Amar U
|
|
|
20 |
12 |
p. e661
|
artikel
|
| 33 |
Optimal patient selection for stereotactic body radiotherapy – Authors' reply
|
Brand, Douglas H
|
|
|
20 |
12 |
p. e662
|
artikel
|
| 34 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
|
Khalaf, Daniel J
|
|
|
20 |
12 |
p. 1730-1739
|
artikel
|
| 35 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
|
Park, Yeon Hee
|
|
|
20 |
12 |
p. 1750-1759
|
artikel
|
| 36 |
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
|
Hui, Rina
|
|
|
20 |
12 |
p. 1670-1680
|
artikel
|
| 37 |
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
|
Laetsch, Theodore W
|
|
|
20 |
12 |
p. 1710-1718
|
artikel
|
| 38 |
Peutz-Jeghers syndrome complicated with intussusception in late pregnancy
|
Li, Zonglin
|
|
|
20 |
12 |
p. e729
|
artikel
|
| 39 |
Post-operative salvage androgen deprivation and radiotherapy for prostate cancer
|
D'Amico, Anthony V
|
|
|
20 |
12 |
p. 1630-1631
|
artikel
|
| 40 |
Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review
|
Mierzynska, Justyna
|
|
|
20 |
12 |
p. e685-e698
|
artikel
|
| 41 |
Promising radiotherapy classifier for early breast cancer
|
Das, Manjulika
|
|
|
20 |
12 |
p. e665
|
artikel
|
| 42 |
Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies
|
Efficace, Fabio
|
|
|
20 |
12 |
p. 1625-1626
|
artikel
|
| 43 |
Quality of life with durvalumab in stage III non-small-cell lung cancer
|
Anota, Amélie
|
|
|
20 |
12 |
p. 1619-1620
|
artikel
|
| 44 |
Radiation-induced cystitis and hyperbaric oxygen therapy
|
Clarke, Richard
|
|
|
20 |
12 |
p. e660
|
artikel
|
| 45 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa, Kazuhiko
|
|
|
20 |
12 |
p. 1655-1669
|
artikel
|
| 46 |
Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study
|
Luo, Huiyan
|
|
|
20 |
12 |
p. 1645-1654
|
artikel
|
| 47 |
Reducing infection-related morbidity and mortality in patients with myeloma
|
Ramasamy, Karthik
|
|
|
20 |
12 |
p. 1633-1635
|
artikel
|
| 48 |
Sebaceous carcinoma: evidence-based clinical practice guidelines
|
Owen, Joshua L
|
|
|
20 |
12 |
p. e699-e714
|
artikel
|
| 49 |
Shedding light on dabrafenib-induced fevers in patients with melanoma
|
Hersey, Peter
|
|
|
20 |
12 |
p. 1637-1638
|
artikel
|
| 50 |
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
|
Carrie, Christian
|
|
|
20 |
12 |
p. 1740-1749
|
artikel
|
| 51 |
The incomplete story of complete mesocolic excision
|
Dossa, Fahima
|
|
|
20 |
12 |
p. e658
|
artikel
|
| 52 |
The incomplete story of complete mesocolic excision – Authors' reply
|
Bertelsen, Claus A
|
|
|
20 |
12 |
p. e659
|
artikel
|
| 53 |
Time to talk about planetary health and cancer care
|
The Lancet Oncology,
|
|
|
20 |
12 |
p. 1615
|
artikel
|
| 54 |
Tumour Treating Fields for mesothelioma: controversy versus opportunity
|
Fennell, Dean A
|
|
|
20 |
12 |
p. 1623-1625
|
artikel
|
| 55 |
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
|
Ceresoli, Giovanni L
|
|
|
20 |
12 |
p. 1702-1709
|
artikel
|
| 56 |
Untapped potential: recognising CNS opportunities in early oncology drug development
|
Patil, Tejas
|
|
|
20 |
12 |
p. 1620-1622
|
artikel
|
| 57 |
Will immunotherapy really change radiotherapy?
|
|
|
|
20 |
12 |
p. 1642-1644
|
artikel
|
Tijdschrift beschrijving